Logo image of PHARM.AS

PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis

AMS:PHARM - Euronext Amsterdam - NL0010391025 - Common Stock - Currency: EUR

0.758  -0.01 (-1.49%)

Fundamental Rating

3

PHARM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. While PHARM seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PHARM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PHARM has reported negative net income.
PHARM had a positive operating cash flow in the past year.
Of the past 5 years PHARM 4 years were profitable.
Of the past 5 years PHARM 4 years had a positive operating cash flow.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

PHARM's Return On Assets of -4.19% is fine compared to the rest of the industry. PHARM outperforms 68.06% of its industry peers.
PHARM's Return On Equity of -7.89% is fine compared to the rest of the industry. PHARM outperforms 69.44% of its industry peers.
Industry RankSector Rank
ROA -4.19%
ROE -7.89%
ROIC N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

PHARM's Gross Margin of 89.39% is amongst the best of the industry. PHARM outperforms 86.11% of its industry peers.
PHARM's Gross Margin has been stable in the last couple of years.
PHARM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

PHARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHARM has more shares outstanding
The number of shares outstanding for PHARM has been increased compared to 5 years ago.
PHARM has a better debt/assets ratio than last year.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

PHARM has an Altman-Z score of 0.41. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
PHARM has a Altman-Z score (0.41) which is in line with its industry peers.
PHARM has a Debt/Equity ratio of 0.53. This is a neutral value indicating PHARM is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.53, PHARM perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Altman-Z 0.41
ROIC/WACCN/A
WACC4.9%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

PHARM has a Current Ratio of 3.53. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.53, PHARM is doing good in the industry, outperforming 69.44% of the companies in the same industry.
PHARM has a Quick Ratio of 2.76. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
PHARM has a better Quick ratio (2.76) than 65.28% of its industry peers.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 2.76
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PHARM have decreased by -3.13% in the last year.
The Revenue has grown by 30.64% in the past year. This is a very strong growth!
PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.35% yearly.
EPS 1Y (TTM)-3.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
Revenue 1Y (TTM)30.64%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%

3.2 Future

Based on estimates for the next years, PHARM will show a very strong growth in Earnings Per Share. The EPS will grow by 41.00% on average per year.
Based on estimates for the next years, PHARM will show a quite strong growth in Revenue. The Revenue will grow by 9.98% on average per year.
EPS Next Y0.22%
EPS Next 2Y6.35%
EPS Next 3Y30.24%
EPS Next 5Y41%
Revenue Next Year18.78%
Revenue Next 2Y13.9%
Revenue Next 3Y12.49%
Revenue Next 5Y9.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M 400M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.1 -0.1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHARM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHARM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -59.86
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as PHARM's earnings are expected to grow with 30.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.35%
EPS Next 3Y30.24%

More info and screens

0

5. Dividend

5.1 Amount

PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMING GROUP NV

AMS:PHARM (3/7/2025, 7:00:00 PM)

0.758

-0.01 (-1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-24 2024-10-24/bmo
Earnings (Next)03-13 2025-03-13/bmo
Inst Owners15.1%
Inst Owner ChangeN/A
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap51.42M
Analysts86.67
Price Target7.15 (843.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-87.38%
Min EPS beat(2)-197.09%
Max EPS beat(2)22.33%
EPS beat(4)1
Avg EPS beat(4)-169.28%
Min EPS beat(4)-363.52%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-130.32%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.45%
Min Revenue beat(2)-5.54%
Max Revenue beat(2)-3.36%
Revenue beat(4)1
Avg Revenue beat(4)-5.41%
Min Revenue beat(4)-21.13%
Max Revenue beat(4)8.39%
Revenue beat(8)3
Avg Revenue beat(8)-5.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-45.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF N/A
P/OCF 123.78
P/B 0.25
P/tB 0.35
EV/EBITDA -59.86
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.81%
SpS3.88
BVpS3.07
TBVpS2.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.19%
ROE -7.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.39%
FCFM N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF N/A
Debt/EBITDA 71.79
Cap/Depr 6.22%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion 27.01%
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 2.76
Altman-Z 0.41
F-Score6
WACC4.9%
ROIC/WACCN/A
Cap/Depr(3y)36.48%
Cap/Depr(5y)146.44%
Cap/Sales(3y)3.32%
Cap/Sales(5y)6.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
EPS Next Y0.22%
EPS Next 2Y6.35%
EPS Next 3Y30.24%
EPS Next 5Y41%
Revenue 1Y (TTM)30.64%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%
Revenue Next Year18.78%
Revenue Next 2Y13.9%
Revenue Next 3Y12.49%
Revenue Next 5Y9.98%
EBIT growth 1Y62.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.14%
EBIT Next 3Y94.6%
EBIT Next 5Y49.92%
FCF growth 1Y-102.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.64%
OCF growth 3YN/A
OCF growth 5YN/A